Q’Apel Medical Raises $22 Million: Funds Will Help Grow a Highly Innovative Neurovascular Access Platform

In addition, Q'Apel Medical reported that Scott Huennekens, former Chairman, CEO and President of Verb Surgical, and Carter McNabb, Managing Director, River Cities Capital, will join the Board of Directors.
Q'Apel Medical

February 11, 2021

Q’Apel Medical notes the round included River Cities Capital, Soleus Capital, and incumbent investor Research Corporation Technologies (RCT). Q’Apel Medical is an innovative neurovascular company specializing in developing and commercializing novel access technology for vascular interventions.

“With our three-pronged approach that involves increasing manufacturing, expanding into newer geographies, and developing innovative products, Q’Apel is perfectly poised to become the preferred catheter technology vendor across the healthcare sector. In addition, having Scott Huennekens and Carter McNabb join our Board of Directors will be extremely valuable. Both Scott and Carter bring extensive experience, especially in high-growth medical device companies, building businesses both in the U.S. and internationally.” said King Nelson, CEO of Q’Apel Medical.

“Q’Apel’s technology has the ability to revolutionize vascular access and improve patient care. There is no better team to lead this effort; between strong existing physician relationships and a deep understanding of the neurovascular market, this team will execute effectively and efficiently,” said Carter McNabb.

“I admire Q’Apel Medical for its highly innovative products and dynamic leadership team, and I’m honored to be joining their board. I have tremendous respect for King, Chris and the other board members, and I look forward to working with them,” said Scott Huennekens

Q’Apel Medical products are already being utilized in over 130 hospital systems nationwide. In 2021, Q’Apel plans to significantly increase its manufacturing capacity, add additional head count and expand their product portfolio. At the same time, the company is in the process of acquiring CE certification, which will allow Q’Apel to expand into Europe later this year.

More

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

The Series B-1 warrants will have an exercise price of $0.85 per share, will be immediately exercisable and will expire 5 years from issuance. The Series B-2 warrants will have an exercise price of $0.85 per share, will be immediately exercisable and will expire 18 months from issuance.

Cofertility Closes Series A Funding, Led by Next Ventures and Offline Ventures, to Revolutionize Fertility and Family Building

The funding will be primarily used towards the further development of Cofertility’s proprietary, user-friendly technology platform, a custom-built egg donor database that streamlines the entire egg donation process, from recruitment and matching to cycle coordination. Already this technology has helped improve the Cofertility experience for its members.